If you have been reading about cold chain and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
=== Pump pressure === Pumps vary in pressure capacity, but their performance is measured on their ability to yield a consistent and reproducible volumetric flow rate. Pressure may reach as high as 60 MPa (6000 lbf/in2), or about 600 atmospheres. Modern HPLC systems have been improved to work at much higher pressures, and therefore are able to use much smaller particle sizes in the columns (<2 μm). These "ultra high performance liquid chromatography" systems or UHPLCs, which could also be known as ultra high pressure chromatography systems, can work at up to 120 MPa (17,405 lbf/in2), or about 1200 atmospheres. The term "UPLC" is a trademark of the Waters Corporation, but is sometimes used to refer to the more general technique of UHPLC.
Compounds with a high ratio of androgenic to an anabolic effects are the drug of choice in androgen-replacement therapy (e.g., treating hypogonadism in males), whereas compounds with a reduced androgenic:anabolic ratio are preferred for anemia and osteoporosis, and to reverse protein loss following trauma, surgery, or prolonged immobilization. Determination of androgenic:anabolic ratio is typically performed in animal studies, which has led to the marketing of some compounds claimed to have anabolic activity with weak androgenic effects. This disassociation is less marked in humans, where all AAS have significant androgenic effects. A commonly used protocol for determining the androgenic:anabolic ratio, dating back to the 1950s, uses the relative weights of ventral prostate (VP) and levator ani muscle (LA) of male rats. The VP weight is an indicator of the androgenic effect, while the LA weight is an indicator of the anabolic effect. Two or more batches of rats are castrated and given no treatment and respectively some AAS of interest. The LA/VP ratio for an AAS is calculated as the ratio of LA/VP weight gains produced by the treatment with that compound using castrated but untreated rats as baseline: (LAc,t–LAc)/(VPc,t–VPc). The LA/VP weight gain ratio from rat experiments is not unitary for testosterone (typically 0.3–0.4), but it is normalized for presentation purposes, and used as basis of comparison for other AAS, which have their androgenic:anabolic ratios scaled accordingly (as shown in the table above).
== Chemistry == Chemically, Parmotrema perlatum contains atranorin and chloroatranorin, alongside a predominant stictic acid chemosyndrome that includes stictic as a major secondary metabolite and smaller amounts of constictic acid and other related substances. Testing the medulla (the inner layer beneath the upper cortex) with spot tests results in K+ (yellow), KC−, and P+ (orange) reactions. The cortical layer, in contrast, is K+ (yellow), KC−, and P−. The secondary metabolites of Parmotrema perlatum have been studied using gas chromatography–mass spectrometry (GC–MS) and liquid chromatography–mass spectrometry (LC–MS/MS). The lichen produces several notable compounds, including orcinol, atraric acid, benzoic acid, 2,4-dihydroxy-3,6-dimethyl-, methyl ester, and palmitic acid, methyl ester. GC–MS analysis revealed the presence of orcinol (63%) and atraric acid (21%) in the methanol extract, while benzoic acid was predominant in the chloroform extract. The hexane extract contained significant amounts of benzoic acid, 2,4-dihydroxy-3,6-dimethyl-, methyl ester (62%). A more recent study using liquid chromatography-electrospray ionization-mass spectrometry/mass spectrometry as an analysis technique tentatively identified a total of twenty-five lichen products, including 5 depsides, 12 depsidones, 2 diphenyl ethers, 1 aromatic considered as possible artifact, 1 dibenzofuran, 1 carbohydrate, 1 organic acid, and 2 undefined compounds.
== Empty commercial property == In April 2009, the UK government established a form of non-commercial leasing for empty commercial properties known as a "meanwhile lease", also referred to as a "meanwhile use lease" (MUL), which aims "to encourage the temporary occupation of empty town centre retail premises by non-commercial occupiers". A set of template leases was made available to enable property owners and tenants to agree a form of lease for temporary occupation. Rents are not charged, or they are low, so that charities, voluntary organisations, learning providers and local artists can occupy the property. No security of tenure is provided so the property can easily be returned to commercial use when the opportunity arises. Loan covenants and debt overhang can contribute to rental vacancy rates.
Sources: en.wikipedia.org
1990) Jack Ridley, American air force officer and test pilot, flew the Bell X-1 jet craft on its inaugural flight; as Jackie Lynwood Ridley, in Garvin, Oklahoma, United States (killed in plane crash, 1957) Died: Scotty Davidson, 24, Canadian hockey player, right wing for the Toronto Blueshirts in 1912 to 1914, helped Toronto win its first Stanley Cup (killed in France) (b. 1892)
=== Hilary Wyndham === Hilary Wyndham (Mark Dexter) is a MD of the FX desk at Pierpoint. Throughout the first season, he is shown to be a more measured leader than his subordinate Kenny, an alcoholic and a bully who repeatedly subjects Yasmin to verbal abuse. However, nearing reduction-in-force (RIF) day, Hilary advises Yasmin not to report Kenny's behavior, telling her that being a "team player" would benefit her career prospects. Yasmin caves to Hilary's advice during her RIF interview when she denies having any negative experiences at Pierpoint, and Hilary vouches for her, ensuring that she is hired. In series 2, Hilary becomes paranoid about contracting COVID-19 at the office, wearing a mask to work and exhibiting germaphobe tendencies. Ironically, it is he who ends up falling ill and having to take time off from the office. Yasmin tells Hilary that she will be spending less time on the FX desk as she explores a move to the Private Wealth Management (PWM) division; Hilary, feeling numb and burnt out from the job, grants her his blessing. Hilary briefly reappears in series 4, now working for the Railways Pension Scheme (RPS); Eric calls him to invest in his and Harper's new short-only fund, SternTao, but Hilary kindly declines, stating that the RPS doesn't share their appetite for risk.
== Animal studies == Meso-zeaxanthin has been tested for animal toxicity by several research teams, who report a lack of toxicity. The NOAEL ('No Observed-Adverse-Effect Level') of meso-zeaxanthin is far greater than doses used in dietary supplements. In 2016, the GRAS ('Generally Regarded As Safe') status of meso-zeaxanthin was acknowledged by the FDA.[1]
==== Australia ==== In March 2021, health regulators in Australia approved the combination for people aged 12 years and older with at least one copy of the F508del mutation. At the end of April 2022, it was placed on the Pharmaceutical Benefits Scheme, thus reducing the cost from tens of thousands of dollars a month, to tens of dollars a month.
1993/169) Combined Probation Areas (Kent) Order 1993 (S.I. 1993/173) Insurance Companies (Amendment) Regulations 1993 (S.I. 1993/174) Council Tax (Transitional Reduction Scheme) (England) Regulations 1993 (S.I. 1993/175) Motor Vehicles (Wearing of Seat Belts) Regulations 1993 (S.I. 1993/176) Loch Crinan Scallops Fishery Order 1993 (S.I. 1993/177) Local Government Act 1988 (Defined Activities) (Specified Periods) (Scotland) Amendment Regulations 1993 (S.I. 1993/178) Air Navigation (Dangerous Goods) (Fourth Amendment) Regulations 1992 S.I. 1993/179) City of London (Non-Domestic Rating Multiplier) Order 1993 (S.I. 1993/180) Sea Fish Licensing (Variation) Order 1993 (S.I. 1993/188) Spring Traps Approval (Variation) Order 1993 (S.I. 1993/189) New Severn Bridge (Restriction of Navigation) Regulations 1993 (S.I. 1993/190) Council Tax and Non-Domestic Rating (Demand Notices) (England) Regulations 1993 (S.I. 1993/191) Value Added Tax Act 1983 (Interest on Overpayments etc.) (Prescribed Rate) Order 1993 (S.I. 1993/192) Copyright (Certification of Licensing Scheme for Educational Recording of Broadcasts and Cable Programmes) (Educational Recording Agency Limited) (Amendment) Order 1993 (S.I. 1993/193) Local Government Finance Act 1992 (Commencement No. 7 and Amendment) Order 1993 (S.I. 1993/194) Council Tax (Reductions for Disabilities) (Amendment) Regulations 1993 (S.I. 1993/195) Council Tax (Administration and Enforcement) (Amendment) Regulations 1993 (S.I. 1993/196) Friendly Societies Act 1992 (Commencement No. 4) Order 1993 (S.I.
Sources: en.wikipedia.org
Feringa and co-workers used this approach in their design of a molecule that can repeatably perform 360° rotation. The full rotation of this molecular motor takes place in four stages. In stages A and C rotation of the aryl moiety is restricted, although helix inversion is possible. In stages B and D the aryl can rotate with respect to the naphthalene with steric interactions preventing the aryl from passing the naphthalene. The rotary cycle consists of four chemically induced steps which realize the conversion of one stage into the next. Steps 1 and 3 are asymmetric ring opening reactions which make use of a chiral reagent in order to control the direction of the rotation of the aryl. Steps 2 and 4 consist of the deprotection of the phenol, followed by regioselective ring formation.
=== Russell indices in Japan === Russell/Nomura equity indices for Japan (calculated with Nomura Securities Co., Ltd.) offer free-float adjusted broad market or style benchmarks for investors in that country.
==== Two states of persistent pain ==== After persistent peripheral tissue damage, there is a release of several factors from the injured tissue as well as in the spinal dorsal horn. These factors increase the responsiveness of the dorsal horn pain-projection neurons to ensuing stimuli, termed "spinal sensitization", thus amplifying the pain impulse to the brain. Release of glutamate, substance P, and calcitonin gene-related peptide (CGRP) mediates NMDAR activation (originally silent because it is plugged by Mg2+), thus aiding in depolarization of the postsynaptic pain-transmitting neurons (PTN). In addition, activation of IP3 signaling and MAPKs (mitogen-activated protein kinases) such as ERK and JNK, bring about an increase in the synthesis of inflammatory factors that alter glutamate transporter function. ERK also further activates AMPARs and NMDARs in neurons. Nociception is further sensitized by the association of ATP and substance P with their respective receptors (P2X3) and neurokinin 1 receptor (NK1R), as well as activation of metabotropic glutamate receptors and release of BDNF. Persistent presence of glutamate in the synapse eventually results in dysregulation of GLT1 and GLAST, crucial transporters of glutamate into astrocytes. Ongoing excitation can also induce ERK and JNK activation, resulting in release of several inflammatory factors. As noxious pain is sustained, spinal sensitization creates transcriptional changes in the neurons of the dorsal horn that lead to altered function for extended periods.
=== Australia === Absinthe is readily available in many bottle shops. Bitters may contain a maximum 35 mg/kg thujone, while other alcoholic beverages can contain a maximum 10 mg/kg. The domestic production and sale of absinthe is regulated by state licensing laws.
Venom or zootoxin is a type of toxin produced by an animal that is actively delivered to other animals through a wound by means of a bite, sting or similar penetrative action, usually via a specially evolved venom apparatus, such as fangs or a stinger, in a process called envenomation. Venoms are often distinguished from poisons, which is passively delivered by being ingested, inhaled, or absorbed through the skin; and toxungen, which is actively transferred to the external surface of another animal via a physical delivery mechanism. Venom has evolved in terrestrial and aquatic environments and in a wide variety of animals: both predators and prey, and both vertebrates and invertebrates. Venoms kill through the action of at least four major classes of toxin, namely necrotoxins and cytotoxins, which kill cells; neurotoxins, which affect nervous systems; myotoxins, which damage muscles; and haemotoxins, which disrupt blood clotting. Venomous animals cause tens of thousands of human deaths per year. Venoms are often complex mixtures of toxins of differing types. Toxins from venom are used to treat a wide range of medical conditions including thrombosis, arthritis, and some cancers. Studies in venomics are investigating the potential use of venom toxins for many other conditions.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.